The voluntary withdrawal of the type 1 diabetes indication for dapagliflozin in the EU by AstraZeneca has been branded as 'appalling' and 'devastating', with questions raised as to why it was pulled.

Results from the anticipated DELIVER trial, presented at the European Society of Cardiology Congress, also showed participants assigned dapagliflozin (Farxiga, AstraZeneca), an SGLT2 inhibitor ...

In this international, randomized, placebo-controlled trial of adult patients hospitalized with confirmed or “strongly suspected” COVID-19, dapagliflozin (Forxiga; AstraZeneca) did not decrease rates ...

The Food and Drug Administration (FDA) has approved updated labeling for Farxiga (dapagliflozin; AstraZeneca) and Xigduo XR (dapagliflozin and metformin HCl extended-release; AstraZeneca) to ...

ASTRAZENECA AND BRISTOL-MYERS SQUIBB ANNOUNCE EXPANSION OF WORLDWIDE COLLABORATION TO DEVELOP AND COMMERCIALISE DAPAGLIFLOZIN IN JAPAN AstraZeneca and Bristol-Myers Squibb today announced ...

PHILADELPHIA, PA—Dapagliflozin (Farxiga; AstraZeneca), originally developed for the treatment of type 2 diabetes, has a broad, positive impact across various subsets of patients with chronic heart ...

Data presented today at the European Society of Cardiology Congress suggest that the benefits of dapagliflozin (Farxiga, AstraZeneca) extend beyond its effects as a diabetes drug.

AstraZeneca Plc's (NASDAQ: AZN) dapagliflozin 5mg (Forxiga/Farxiga) was authorized in 2019 as an adjunct to insulin in patients with type 1 diabetes with a body-mass index (BMI) ...

Bristol-Myers Squibb and AstraZeneca announced positive results from a Phase 3 study of dapagliflozin as add-on therapy to metformin for the treatment of type 2 diabetes. This 24-week, randomized ...

astrazeneca | dapagliflozin | heart failure. Related posts. Levicept presents new LEVI-04 data at EULAR. Jun 12, 2025. Migraine takes the spotlight at European Parliament. Jun 12, 2025. Bimekizumab ...

A discussion with Naeem Khan, MD, vice president of US cardiovascular and metabolic diseases at AstraZeneca, on lessons from the wave of cardiovascular outcomes trials, the new focus on renal ...

AstraZeneca then added a second primary end point to its cardiovascular outcomes trial, DECLARE-TIMI 58, and results released in November 2018 showed that dapagliflozin significantly reduced the ...